Egyptian International Pharmaceutical Industries’ (EIPICO) ordinary general meeting (OGM) has endorsed the company’s 2018 financial statements.
The OGM also approved a cash dividend distribution for FY18 of EGP 396.6 million to shareholders and EGP 62.3 million to employees, EIPICO said in a statement to the Egyptian Exchange (EGX) on Wednesday.
Additionally, the OGM has approved the board’s and audit’s reports on FY18 financial statements.
Meanwhile, the extraordinary general meeting (EGM) has decided to amend the article no.4 of the company’s articles of association.
In March, EIPICO reported an EGP 701.31 million in net consolidated profits for FY18, versus EGP 688.87 million in FY17.